Role of long noncoding RNAs in the regulation of alternative splicing in glioblastoma

2024-10-1

On the pivotal role of drug discovery in sustainable EU pharma reform

2024-10-1

Regulatory readiness to facilitate the appropriate use of innovation in clinical trials: The case of decentralized clinical trial approaches

2024-9-1

The regulatory mechanism of natural polysaccharides in type 2 diabetes mellitus treatment

2024-9-1

Rewriting the textbook for pharma: how to adapt and thrive in a digital, personalized and collaborative world

2024-9-1

Embryonic and larval zebrafish models for the discovery of new bioactive compounds against TB

2024-9-1

Deciphering immune responses: a comparative analysis of influenza vaccination platforms

2024-9-1

Comparative analysis of FDA approvals by top 20 pharma companies (2014–2023)

2024-9-1

Neurotrophin peptidomimetics for the treatment of neurodegenerative diseases

2024-9-1

Expression, regulation, and function of PD-L1 on non-tumor cells in the tumor microenvironment

2024-9-1

Targeted protein degradation: current molecular targets, localization, and strategies

2024-9-1

Therapies for Inherited Retinal Dystrophies: What is Enough?

2024-9-1

Collaborative GSK–University of Strathclyde doctoral research and training programmes: Transforming approaches to industry–academia engagement

2024-9-1

P-glycoprotein (P-gp)-driven cancer drug resistance: biological profile, non-coding RNAs, drugs and nanomodulators

2024-9-1

MicroRNAs and therapeutic potentials in acute and chronic cardiac disease

2024-9-1

Clinical strategies with antibody–drug conjugates as potential modifications for virotherapy

2024-9-1

Aging and cognitive resilience: Molecular mechanisms as new potential therapeutic targets

2024-9-1

The pharmaceutical productivity gap – incremental decline in R&D efficiency despite transient improvements

2024-9-1

New developments in celiac disease treatments

2024-9-1

Machine learning and natural language processing in clinical trial eligibility criteria parsing: a scoping review

2024-8-19

Designed dualsteric modulators: A novel route for drug discovery

2024-8-19

Multidisciplinary considerations for implementing Bayesian borrowing in basket trials

2024-8-3

Navigating the frontier of drug-like chemical space with cutting-edge generative AI models

2024-8-3

Are protein–ligand docking programs good enough to predict experimental poses of noncovalent ligands bound to the SARS-CoV-2 main protease?

2024-8-1

Hit me with your best shot: Integrated hit discovery for the next generation of drug targets

2024-8-1

Targeting eukaryotic elongation factor 2 kinase (eEF2K) with small-molecule inhibitors for cancer therapy

2024-8-1

Selenium-containing compounds: a new hope for innovative treatments in Alzheimer’s disease and Parkinson’s disease

2024-8-1

Pharmaceutical innovation and advanced biotechnology in the biotech-pharmaceutical industry for antibody–drug conjugate development

2024-8-1

Advances in structure-based drug design targeting membrane protein markers in prostate cancer

2024-8-1

Machine learning for antidepressant treatment selection in depression

2024-8-1

Recent innovations in topical delivery for management of rheumatoid arthritis: A focus on combination drug delivery

2024-8-1

Lipid- and polymer-based formulations containing TNF-α inhibitors for the treatment of inflammatory bowel diseases

2024-8-1

An overview of the development of pharmacotherapeutics targeting SARS-CoV-2

2024-8-1

The efficacy and safety of eculizumab in patients and the role of C5 polymorphisms

2024-8-1

Promoting the social implementation of digital and mobile health: effects of regulation on user and non-user behavior in East Asia

2024-8-1

Endolysosomal trapping of therapeutics and endosomal escape strategies

2024-8-1

Targeting neuroinflammation in distal symmetrical polyneuropathy in diabetes

2024-8-1

Block copolymer micelles as ocular drug delivery systems

2024-8-1

Unveiling the role of the Hedgehog signaling pathway in chronic liver disease: Therapeutic insights and strategies

2024-8-1

Oxygen-generating biomaterials for cardiovascular engineering: unveiling future discoveries

2024-8-1

Antitoxin nanoparticles: design considerations, functional mechanisms, and applications in toxin neutralization

2024-8-1

Targeting hematological malignancies with isoxazole derivatives

2024-8-1

Molecular insights to therapeutic in cancer: role of exosomes in tumor microenvironment, metastatic progression and drug resistance

2024-8-1

Preclinical alternative drug discovery programs for monogenic rare diseases. The case of hereditary spastic paraplegias

2024-8-1

Exploration of inhibitors targeting KIF18A with ploidy-specific lethality

2024-8-1

Mechanical network motifs as targets for mechanomedicine

2024-8-1

Targeting shelterin proteins for cancer therapy

2024-8-1

Chemical coverage of human biological pathways

2024-8-1

Repurposing cardiac glycosides for anticancer treatment: a review of clinical studies

2024-8-1

Three-dimensional cell culture: Future scope in cancer vaccine development

2024-7-26